Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.

[1]  P. Belperio,et al.  Impact of Sustained Virologic Response with Direct‐Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease , 2019, Hepatology.

[2]  Albert Tran,et al.  Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. , 2018, Gastroenterology.

[3]  G. Giannelli,et al.  Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals , 2018, Hepatology.

[4]  Giovanni Raimondo,et al.  Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.

[5]  A. Alberti,et al.  Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. , 2018, Journal of hepatology.

[6]  A. Singal,et al.  Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy , 2018, Alimentary pharmacology & therapeutics.

[7]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[8]  F. Farinati,et al.  HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue? , 2018, Hepatoma Research.

[9]  R. Chung,et al.  The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study , 2018, Hepatology.

[10]  A. Fontanet,et al.  Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C‐infected Egyptian cohort: A comparative analysis , 2018, Journal of viral hepatitis.

[11]  C. Datz,et al.  Follow‐up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin‐free treatment , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[12]  J. Raoul,et al.  Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case–control study , 2018, European journal of gastroenterology & hepatology.

[13]  B. John,et al.  Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy , 2018, Current Treatment Options in Gastroenterology.

[14]  Christoph Sarrazin,et al.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals , 2018, Liver Cancer.

[15]  A. Butt,et al.  Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon? , 2018, World journal of hepatology.

[16]  G. Cabibbo,et al.  Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact? , 2018, Expert review of anticancer therapy.

[17]  M. Colombo,et al.  Hepatitis C eradication with DAA and risk of liver cancer recurrence: The debate unrests , 2018, Journal of viral hepatitis.

[18]  D. Samuel,et al.  The impact of treatment of hepatitis C with DAAs on the occurrence of HCC , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[19]  H. Nomura,et al.  Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment , 2018, Alimentary pharmacology & therapeutics.

[20]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[21]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[22]  P. Hayes,et al.  The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. , 2017, Journal of hepatology.

[23]  Masahiro Ito,et al.  Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy? , 2017, Journal of hepatology.

[24]  G. Dore,et al.  Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot". , 2017, Journal of hepatology.

[25]  G. D’Amico,et al.  Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  C. Camma',et al.  Direct antiviral agents and risk of HCC: Waiting for Godot. , 2017, Journal of hepatology.

[27]  H. Shousha,et al.  De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus , 2018, European journal of gastroenterology & hepatology.

[28]  R. Golfieri,et al.  Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis , 2018, European Radiology.

[29]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[30]  S. Kakinuma,et al.  Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. , 2017, Journal of hepatology.

[31]  C. Van Steenkiste,et al.  The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience , 2017, Journal of viral hepatitis.

[32]  T. Liang,et al.  Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. , 2017, Gastroenterology.

[33]  M. Kudo,et al.  Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection , 2017, Digestive Diseases.

[34]  T. Berg,et al.  Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. , 2017, Journal of hepatology.

[35]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[36]  Yoshiyuki Suzuki,et al.  Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma , 2017, Digestive Diseases and Sciences.

[37]  J. Feld,et al.  Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed? , 2017, Gastroenterology.

[38]  M. Imamura,et al.  The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy , 2017, PloS one.

[39]  G. Cabibbo,et al.  Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study , 2017, Alimentary pharmacology & therapeutics.

[40]  G. Giannelli,et al.  Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study , 2017, Cell Death & Disease.

[41]  M. Colombo,et al.  A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[42]  C. Combet,et al.  Direct‐acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[43]  A. Gasbarrini,et al.  Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. , 2017, Journal of hepatology.

[44]  C. Frenette,et al.  Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection. , 2017, Gastroenterology & hepatology.

[45]  H. Saito,et al.  On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C , 2017, PloS one.

[46]  J. Jakobsen,et al.  Direct-acting antivirals for chronic hepatitis C. , 2017, The Cochrane database of systematic reviews.

[47]  F. Jorquera,et al.  Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. , 2017, Journal of hepatology.

[48]  M. Nagata,et al.  Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals , 2017, Indian Journal of Gastroenterology.

[49]  Yoshiyuki Suzuki,et al.  Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease , 2017, Oncology.

[50]  A. Singal,et al.  Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. , 2017, Gastroenterology.

[51]  Yoshiyuki Suzuki,et al.  Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection , 2017, Journal of medical virology.

[52]  O. Weiland,et al.  Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. , 2017, Journal of hepatology.

[53]  A. Gasbarrini,et al.  Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon , 2017, Alimentary pharmacology & therapeutics.

[54]  G. Ioannou,et al.  HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. , 2017, Journal of hepatology.

[55]  S. Okolicsanyi,et al.  Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? , 2017, Journal of hepatology.

[56]  M. Ziol,et al.  Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.

[57]  A. Facciorusso,et al.  DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment , 2016, PloS one.

[58]  K. Koike,et al.  The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. , 2016, Journal of hepatology.

[59]  S. BrownRobert.  The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence. , 2016 .

[60]  Marco Silva,et al.  High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. , 2016, Journal of hepatology.

[61]  J. Vauthey,et al.  Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. , 2016, Journal of hepatology.

[62]  A. Walker,et al.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[63]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[64]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[65]  R. Stauber,et al.  Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. , 2016, Journal of hepatology.

[66]  G. Cabibbo,et al.  Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. , 2016, Journal of hepatology.

[67]  M. Colombo,et al.  Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. , 2016, Journal of hepatology.

[68]  A. Moorman,et al.  Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma , 2016, Journal of viral hepatitis.

[69]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[70]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[71]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[72]  B. Carr,et al.  A Hepatocellular Carcinoma Aggressiveness Index and Its Relationship to Liver Enzyme Levels , 2016, Oncology.

[73]  Peter J. Richardson,et al.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection , 2016, Hepatology.

[74]  R. D. de Knegt,et al.  Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. , 2016, The Journal of infectious diseases.

[75]  L. Rinaldi,et al.  HEPATOCELLULAR CARCINOMA IN HCV CIRRHOSIS AFTER VIRAL CLEARANCE WITH DIRECT ACTING ANTIVIRAL THERAPY : PRELIMINARY EVIDENCE AND POSSIBLE MEANINGS , 2016 .

[76]  M. Burchill,et al.  Memory re‐differentiation and reduced lymphocyte activation in chronic HCV‐infected patients receiving direct‐acting antivirals , 2015, Journal of viral hepatitis.

[77]  J. McCluskey,et al.  The burgeoning family of unconventional T cells , 2015, Nature Immunology.

[78]  R. Schooley,et al.  Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection , 2015, Hepatology.

[79]  T. Liang,et al.  Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. , 2015, Gastroenterology.

[80]  Gianluigi Giannelli,et al.  Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study , 2015, Gut.

[81]  A. Folgori,et al.  T‐cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon‐free antiviral regimen in a chimpanzee , 2014, Hepatology.

[82]  G. Kukolj,et al.  Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. , 2014, Journal of hepatology.

[83]  G. D’Amico,et al.  Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients , 2014, Alimentary pharmacology & therapeutics.

[84]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[85]  N. Enomoto,et al.  α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C , 2013, Hepatology.

[86]  O. Weiland,et al.  A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  Bryce D. Smith,et al.  Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma , 2013, Annals of Internal Medicine.

[88]  R. Chung,et al.  Hepatitis C virus and hepatocarcinogenesis , 2012, Clinical and molecular hepatology.

[89]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[90]  S. Lemon,et al.  Is hepatitis C virus carcinogenic? , 2012, Gastroenterology.

[91]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[92]  M. Manns,et al.  Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus , 2008, Hepatology.

[93]  S. Fan,et al.  Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma , 2000, Cancer.

[94]  Y. Liaw,et al.  Alpha fetoprotein and hepatic regeneration. , 1979, Gastroenterology.